BioSpace News Archive

Specialty cancer diagnostics company Precipio, Inc. presented at the annual 2022 AMP conference a poster presentation of the results of a groundbreaking study, conducted in collaboration with faculty at the University of Pennsylvania.

MDimune, Inc., a Korean biotech company developing BioDrone™ platform technology based on cell-derived vesicles (CDVs), announced a business agreement with Ewha Womans University Medical Center (EUMC) and acquisition of IP from EUMC to develop therapeutics for inflammatory bowel diseases (IBD). MDimune and EUMC agreed to extend their research collaboration which will play a pivotal role in innovative IBD drug development.

The global Inflammatory Bowel Disease Treatment market size was estimated at USD 25.20 billion in 2022 and is expected to surpass around USD 40.8 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.1% during the forecast period 2022 to 2030.

According to Nova one advisor, the global Head And Neck Cancer Therapeutics market was valued at USD 1.40 billion in 2021 and it is expected to hit around USD 3.80 billion by 2030 with a CAGR of 12.9% during the forecast period 2022 to 2030.